Company profile: Regor Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage discovery and development of medicines for oncology, metabolic, and autoimmune diseases, powered by its proprietary rCARD platform for accelerated drug discovery. Pipeline includes RGT-075, an oral once-daily GLP-1R agonist for obesity, and RGT-419B, a CDK4/6 inhibitor for advanced/metastatic breast cancer, showing efficacy in patients resistant to current therapies.
Products and services
- RCARD: Proprietary, computer-accelerated discovery platform integrating structural biology, computational chemistry, therapeutic biology, and medicinal chemistry to expedite discovery and development of innovative, clinically differentiated medicines
- RGT-075: Oral GLP-1R agonist engineered for obesity, once-daily administration enabling receptor-specific activation for metabolic disease management
- RGT-419B: CDK4/6-directed inhibitor developed for advanced/metastatic breast cancer, demonstrating efficacy in patients resistant to current therapies, supporting treatment in refractory cases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Regor Therapeutics
Auron Therapeutics
HQ: United States
Website
- Description: Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auron Therapeutics company profile →
Pheon Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pheon Therapeutics company profile →
Armune Bioscience
HQ: United States
Website
- Description: Provider of molecular diagnostic and prognostic tests for prostate, lung and breast cancers, enabling physicians and patients to make more personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Armune Bioscience company profile →
Quanticel
HQ: United States
Website
- Description: Provider of oncology drug discovery, leveraging a proprietary single-cell genomic analysis platform for human cancer to enable the discovery and development of breakthrough, first-in-class cancer therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanticel company profile →
OncoVista Innovative Therapies
HQ: United States
Website
- Description: Provider of anticancer therapy development utilizing tumor-associated biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoVista Innovative Therapies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Regor Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Regor Therapeutics
2.2 - Growth funds investing in similar companies to Regor Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Regor Therapeutics
4.2 - Public trading comparable groups for Regor Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →